Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 46 points (-0.3%) at 15,208 as of Tuesday, June 4, 2013, 12:49 PM ET. The NYSE advances/declines ratio sits at 1,093 issues advancing vs. 1,832 declining with 114 unchanged. The Drugs industry currently sits down 1.02 versus the S&P 500, which is down 0.24. On the negative front, top decliners within the industry include Biogen Idec ( BIIB), down 3.29, Alexion Pharmaceuticals ( ALXN), down 2.16, Eli Lilly and Company ( LLY), down 1.05, Abbott Laboratories ( ABT), down 0.71 and AstraZeneca ( AZN), down 0.68. TheStreet Ratings group would like to highlight 5 stocks pushing the industry lower today: 5. Celgene Corporation ( CELG) is one of the companies pushing the Drugs industry lower today. As of noon trading, Celgene Corporation is down $2.46 (-2.0%) to $118.43 on average volume Thus far, 1.6 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 3.2 million shares. The stock has ranged in price between $118.32-$121.44 after having opened the day at $120.92 as compared to the previous trading day's close of $120.89. Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and immune-inflammatory related diseases in the United States, Europe, and other countries. Celgene Corporation has a market cap of $51.6 billion and is part of the health care sector. The company has a P/E ratio of 37.6, above the S&P 500 P/E ratio of 17.7. Shares are up 57.6% year to date as of the close of trading on Monday. Currently there are 21 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 4 rate it a hold. TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, expanding profit margins, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Celgene Corporation Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.